์กฐ์ง ๋ฐ ๊ณ์ฝ ๊ฐ๊ฒฉ์ ๋ณด๋ ค๋ฉด ๋ก๊ทธ์ธ๋ฅผ ํด๋ฆญํฉ๋๋ค.
ํฌ๊ธฐ ์ ํ
๋ณด๊ธฐ ๋ณ๊ฒฝ
์ ํ์ ๋ณด (DICE ๋ฐฐ์ก ์ ๋น์ฉ ๋ณ๋)
๊ธฐ์ ์๋น์ค
๋์์ด ํ์ํ์ ๊ฐ์? ์ ํฌ ์๋ จ๋ ๊ณผํ์ ํ์ด ๋์๋๋ฆฌ๊ฒ ์ต๋๋ค.
๋์ ๋ฌธ์biological source
human placenta
Quality Level
grade
Molecular Biology
form
buffered aqueous solution
mol wt
~50 kDa
concentration
30,000-50,000 units/mL
shipped in
dry ice
storage temp.
−20ยฐC
General description
Ribonuclease inhibitor works to inhibit RNase activity by forming a tight, non-covalent 1:1 complex. It is human placenta. It inhibits RNases A, B, and C. It will not inhibit RNases H, 1, T1, S1 Nuclease, SP6, T7 RNA Polymerase, T3 RNA Polymerase, AMV Reverse Transcriptase, M-MLV Reverse Transcriptase, or Taq Polymerase. The inhibitor can be removed by phenol extraction or by heating to 65ยฐC for 10 minutes.
Application
Useful for in vitro inhibition of ribonucleases, including procedures like cDNA synthesis, RT-PCR, and in vitro transcription and translation.
Suitable for use in
- in vitro inhibition of ribonucleases
- cDNA synthesis
- RT-PCR
- in vitro transcription and translation
Biochem/physiol Actions
Inhibits RNase by forming a tight, non-covalent 1:1 complex.
Inhibits RNase by forming a tight, non-covalent 1:1 complex. Also inhibits angiogenin, a neovascularization promoter which is homologous with RNase A.
Physical form
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT
Other Notes
One unit will reduce the activity of 5 ng of ribonuclease A by 50% in a cytidine 2โฒ:3โฒ-cyclic monophosphate system.
Ribonuclease Inhibitor is provided as a solution in 20 mM HEPES-KOH( pH 7.6), 50 mM KCl, 8 mM DTT and 50% glycerol.
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT
This inhibitor of RNase activity is isolated from human placenta and supplied as a buffered aqueous glycerol solution.
์ ์ฅ ๋ฑ๊ธ
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
๊ฐ์ฅ ์ต์ ๋ฒ์ ์ค ํ๋๋ฅผ ์ ํํ์ธ์:
์ด ์ ํ์ ์ด๋ฏธ ๊ฐ์ง๊ณ ๊ณ์ญ๋๊น?
๋ฌธ์ ๋ผ์ด๋ธ๋ฌ๋ฆฌ์์ ์ต๊ทผ์ ๊ตฌ๋งคํ ์ ํ์ ๋ํ ๋ฌธ์๋ฅผ ์ฐพ์๋ณด์ธ์.
๊ด๋ จ ์ฝํ ์ธ
Ribonuclease inhibitor from human placenta: interaction with derivatives of ribonuclease A.
P Blackburn et al.
The Journal of biological chemistry, 254(24), 12488-12493 (1979-12-25)
Sabahattin Kaymakoglu et al.
Antimicrobial agents and chemotherapy, 49(3), 1135-1138 (2005-02-25)
The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is very limited. In this study, the efficacy of IFN-alpha and ribavirin combination therapy for chronic hepatitis D was investigated. Nineteen patients (15 males; mean age
Michal Mikula et al.
The Journal of biological chemistry, 286(11), 9763-9775 (2011-01-15)
Components of the ERK cascade are recruited to genes, but it remains unknown how they are regulated at these sites. The RNA-binding protein heterogeneous nuclear ribonucleoprotein (hnRNP) K interacts with kinases and is found along genes including the mitogen-inducible early
๊ตญ์ ๋ฌด์ญ ํ๋ชฉ ๋ฒํธ
| SKU | GTIN |
|---|---|
| R2520-2.5KU | 04061835574759 |
| R2520-10KU | 04061833655184 |
| R2520-20KU | 04061833655191 |